Who owns AMPHASTAR PHARMACEUTICALS IN?
- CUSIP Number: 03209rab9
Tip: Access positions for across all investors
Analyze quarterly positions in Amphastar Pharmaceuticals In with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Amphastar Pharmaceuticals In stock
Who bought or sold AMPHASTAR PHARMACEUTICALS IN this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Linden Advisors | 94M | $87M | 0% | Dec 2025 |
|
| Camden Asset Management | 37M | $34B | 0% | Dec 2025 |
|
| Context Capital Management | 32M | $29M | 165004% | Dec 2025 |
|
| Wellesley Investment Advisors | 20M | $18B | -53% | Dec 2025 |
|
| Oaktree Capital Management | 18M | $16M | 100% | Sep 2025 |
|
| Tenor Capital Management | 15M | $14M | 100% | Sep 2025 |
|
| Empyrean Capital Partners | 15M | $14M | 0% | Sep 2025 |
|
| Silverback Asset Management | 10M | $9.1M | 103% | Sep 2025 |
|
| Calamos Advisors | 10M | $9.2M | 0% | Dec 2025 |
|
| MacKay Shields | 8.7M | $8.1M | -25% | Dec 2025 |
|
| Russell Investments | 6.4M | $5.9M | 66% | Dec 2025 |
|
| BlackRock | 4.4M | $4.0M | 26% | Dec 2025 |
|
| Advent Capital Management | 4.1M | $3.8M | 27% | Dec 2025 |
|
| FMR | 3.8M | $3.4M | -16% | Sep 2025 |
|
| CSS | 2.5M | $2.3M | -2% | Dec 2025 |
|
| Kim | 2.5M | $2.3M | 0% | Dec 2025 |
|
| Palisade Capital Management | 2.5M | $2.3M | 0% | Sep 2025 |
|
| Lazard Asset Management | 2.5M | $23k | 162% | Dec 2025 |
|
| Royal Bank of Canada | 2.1M | $1.9M | 100% | Sep 2025 |
|
| Cutler Capital Management | 2.0M | $1.8M | 0% | Dec 2025 |
|
| Jpmorgan Chase & Co | 1.7M | $1.6M | 100% | Sep 2025 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 1.2M | $1.1M | 0% | Dec 2025 |
|
| SSI Investment Management | 367k | $338k | 0% | Dec 2025 |
|
| Leucadia National Corporation | 318k | $294k | -93% | Dec 2025 |
|
| Bank of New York Mellon | 300k | $278k | 0% | Dec 2025 |
|
| Zurcher Kantonalbank | 250k | $231k | 0% | Dec 2025 |
|
| Barclays | 242k | $224k | 100% | Dec 2025 |
|
| Sei Investments | 139k | $128k | 0% | Dec 2025 |
|
| Cetera Investment Advisers | 111k | $102k | 0% | Dec 2025 |
|
| Raymond James Financial | 38k | $35k | 171% | Dec 2025 |
|
| Rsm Us Wealth Management | 37k | $34k | 0% | Dec 2025 |
|
| Capital Investment Advisory Services | 16k | $15k | 0% | Dec 2025 |
|
| Goldman Sachs Group | 16k | $15k | 0% | Dec 2025 |
|
| Insigneo Advisory Services | 15k | $14k | 36% | Dec 2025 |
|
| Brian McDonald | 11k | $10k | 0% | Dec 2025 |
|
| Wealth Enhancement Advisory Services | 10k | $9.3k | 100% | Dec 2025 |
|
| Wells Fargo & Company | 4.0k | $3.7k | -100% | Dec 2025 |
|
| Steward Partners Investment Advisory | 4.0k | $3.7k | 0% | Dec 2025 |
|
| Advisor Group Holdings | 6.00 | $5.5k | 0% | Dec 2025 |
|
Who sold out of Amphastar Pharmaceuticals In?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Branch Banking & Trust Company | Sep 2025 | 511k | $463k |
| Jane Street | Sep 2025 | 100k | $91k |
| Oppenheimer Asset Management | Sep 2025 | 85k | $77k |
| Stephens | Sep 2025 | 26k | $24k |
| Nomura Holdings | Sep 2025 | 23k | $610k |
| Balboa Wealth Partners | Sep 2025 | 14k | $13k |
| Fifth Third Bancorp | Sep 2025 | 5.0k | $453k |